出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2013/02/01 15:50:09」(JST)[Wiki en表示]
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
- 1. 非プラチナ製剤ベースの癌化学療法の神経学的合併症の概要 overview of neurologic complications of non platinum cancer chemotherapy
- 2. 成人における抗癌剤の投与 dosing of anticancer agents in adults
- 3. 化学療法誘発性末梢神経障害の予防および治療 prevention and treatment of chemotherapy induced peripheral neuropathy
- 4. Management of resistant or recurrent gestational trophoblastic neoplasia
- 5. Initial management of high-risk gestational trophoblastic neoplasia
- Chronic immune thrombocytopenia in childhood.
- Del Vecchio GC1, De Santis A, Accettura L, De Mattia D, Giordano P.Author information 1aDepartment of Biomedical Sciences and Human Oncology, Pediatric Unit 'F. Vecchio', Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari bStruttura Complessa di Pediatria, Ospedale "Umberto I", ASL BA, Altamura, Bari, Italy.AbstractChronic thrombocytopenias are pathological conditions defined as a persistent platelet count below the normal range for more than 6-12 months, clinically characterized by mucocutaneous bleeding. Recently, an International Working Group of expert clinicians has redefined standard terminology and definitions of primary and secondary chronic immune thrombocytopenia (ITP). A document issued on acute childhood idiopathic thrombocytopenic purpura (AIEOP) provides parents and physicians with guidelines for the management of chronic ITP and gives prominence to the periodic re-evaluation of differential diagnosis. The majority of chronic ITP children do not require pharmacological treatments, especially if symptoms are absent or minimal and the treatment decision depends on several factors, in particular clinical conditions rather than platelets count. The recommendations distinguish three therapeutic strategies: emergency or symptomatic treatment, maintenance therapy and treatment aiming at definitive remission. Experimental/off-label treatment of chronic ITP are reported in the literature, such as the use of rituximab. Currently, other drugs (thrombopoiesis stimulating factors, mycophenolate, dapsone, danazol, azathioprine, rFVIIa, cyclophosphamide, vinca alkaloids and cyclosporine) are recommended in special cases or trials.
- Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.Blood Coagul Fibrinolysis.2014 Jun;25(4):297-299.
- Chronic thrombocytopenias are pathological conditions defined as a persistent platelet count below the normal range for more than 6-12 months, clinically characterized by mucocutaneous bleeding. Recently, an International Working Group of expert clinicians has redefined standard terminology and defi
- PMID 24492401
- Recent advances regarding the role of ABC subfamily C member 10 (ABCC10) in the efflux of antitumor drugs.
- Kathawala RJ1, Wang YJ, Ashby Jr CR, Chen ZS.Author information 1Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, Queens, NY 11439, USA. firstname.lastname@example.org.AbstractABCC10, also known as multidrug-resistant protein 7 (MRP7), is the tenth member of the C subfamily of the ATP-binding cassette (ABC) superfamily. ABCC10 mediates multidrug resistance (MDR) in cancer cells by preventing the intracellular accumulation of certain antitumor drugs. The ABCC10 transporter is a 171-kDa protein that is localized on the basolateral cell membrane. ABCC10 is a broad-specificity transporter of xenobiotics, including antitumor drugs, such as taxanes, epothilone B, vinca alkaloids, and cytarabine, as well as modulators of the estrogen pathway, such as tamoxifen. In recent years, ABCC10 inhibitors, including cepharanthine, lapatinib, erlotinib, nilotinib, imatinib, sildenafil, and vardenafil, have been reported to overcome ABCC10-mediated MDR. This review discusses some recent and clinically relevant aspects of the ABCC10 drug efflux transporter from the perspective of current chemotherapy, particularly its inhibition by tyrosine kinase inhibitors and phosphodiesterase type 5 inhibitors.
- Chinese journal of cancer.Chin J Cancer.2014 May 5;33(5):223-230. doi: 10.5732/cjc.013.10122. Epub 2013 Oct 9.
- ABCC10, also known as multidrug-resistant protein 7 (MRP7), is the tenth member of the C subfamily of the ATP-binding cassette (ABC) superfamily. ABCC10 mediates multidrug resistance (MDR) in cancer cells by preventing the intracellular accumulation of certain antitumor drugs. The ABCC10 transporter
- PMID 24103790
- Pathological Status of Mediastinal Lymph Nodes after Preoperative Concurrent Chemoradiotherapy Determines Prognosis in Patients with Non-Small Cell Lung Cancer
- Shintani Yasushi,Funakoshi Yasunobu,Inoue Masayoshi,Takeuchi Yukiyasu,Okumura Meinoshin,Maeda Hajime,Ohta Mitsunori
- Annals of Thoracic and Cardiovascular Surgery 18(6), 530-535, 2012
- … Each received 2 cycles of cisplatin-vinca alkaloid-based chemotherapy every 4 weeks. …
- NAID 130002148298
- Synthesis of vinca alkaloids and related compounds (part 109) An intramolecular <4+2> cycloaddition mediated biomimetic synthesis of (±)-iboxyphylline
- Toth Florian,Kalaus Gyorgy,Pipa Gergely [他]
- Heterocycles 75(1), 65-76, 2008-01-01
- NAID 40015919659
- What are vinca alkaloids? Vinca alkaloids are a material of a class of organic compounds made up of carbon, hydrogen, nitrogen and oxygen that is often derived from plants is named alkaloid. Although, the name ...
- (med) any of a group of alkaloids obtained from the periwinkle Vinca rosea, such as vinblastine and vincristine, that interfere with cell division and are used in the treatment of cancer ...
- vinca alkaloid
- specific agents (bella- donna; ergot; muscarinic, gangli- onic, and neuromuscular agents)
- genus Vinca